# Relay Therapeutics Inc. (RLAY) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $19.04, market value $4.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Relay Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 403.2×**. Each dollar of revenue is priced at 403.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -48.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -46.0%**. Each dollar of assets produces -46.0% of profit.

## Growth
- **Revenue growth (1 yr): 53.4%** (3-yr 123.2%/yr, 5-yr -28.6%/yr). Revenue grew 53.4% over the last year, against -28.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 31.8%**. Earnings per share rose 31.8%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 22.61** (quick 22.61). Current assets cover the next year's liabilities 22.61 times.
- **Altman Z-score: 46.89**. A Z-score of 46.89 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Relay Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Relay Therapeutics Inc.; the consensus is strong_buy, with an average price target of $27.08 (+42% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 376.0%** (YTD 125.1%, 3-mo 40.8%). The shares are up 376.0% over twelve months including dividends.
- **From 52-week high: -10.5%** (392.6% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 1.65** (volatility 69%). Beta of 1.65 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RLAY · Page: https://foliofundamentals.com/stocks/rlay

Not investment advice.